Hussman Strategic Advisors Inc. grew its position in Evolent Health, Inc (NYSE:EVH - Free Report) by 66.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 105,000 shares of the technology company's stock after acquiring an additional 42,000 shares during the period. Hussman Strategic Advisors Inc. owned about 0.09% of Evolent Health worth $994,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Signaturefd LLC raised its position in shares of Evolent Health by 400.6% during the 1st quarter. Signaturefd LLC now owns 7,043 shares of the technology company's stock worth $67,000 after purchasing an additional 5,636 shares during the last quarter. Rock Point Advisors LLC raised its position in shares of Evolent Health by 37.6% during the 1st quarter. Rock Point Advisors LLC now owns 824,535 shares of the technology company's stock worth $7,808,000 after purchasing an additional 225,396 shares during the last quarter. 49 Wealth Management LLC acquired a new position in shares of Evolent Health during the 1st quarter worth about $185,000. Values First Advisors Inc. raised its position in shares of Evolent Health by 77.0% during the 1st quarter. Values First Advisors Inc. now owns 46,444 shares of the technology company's stock worth $441,000 after purchasing an additional 20,204 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in shares of Evolent Health during the 1st quarter worth about $137,000.
Evolent Health Stock Performance
Evolent Health stock opened at $9.54 on Friday. The firm has a 50 day simple moving average of $9.47 and a 200-day simple moving average of $9.81. Evolent Health, Inc has a 1-year low of $7.06 and a 1-year high of $33.63. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.98 and a quick ratio of 0.98. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -7.76 and a beta of 1.01.
Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The technology company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by ($0.02). The company had revenue of $483.65 million for the quarter, compared to analysts' expectations of $460.15 million. Evolent Health had a positive return on equity of 3.64% and a negative net margin of 4.54%. The business's revenue for the quarter was down 24.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.34 EPS. On average, analysts expect that Evolent Health, Inc will post 0.08 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on EVH. Truist Financial upped their price objective on shares of Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday. UBS Group upped their price objective on shares of Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Needham & Company LLC reaffirmed a "buy" rating and set a $15.00 price objective on shares of Evolent Health in a research note on Tuesday, May 13th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $13.00 price objective on shares of Evolent Health in a research note on Friday, June 20th. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Evolent Health presently has a consensus rating of "Buy" and a consensus target price of $17.93.
Read Our Latest Stock Analysis on EVH
About Evolent Health
(
Free Report)
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.